搜索筛选:
搜索耗时0.0717秒,为你在为你在102,285,761篇论文里面共找到 10 篇相符的论文内容
发布年度:
[会议论文] 作者：Yiwu Yao,Zhengchao Tu,Sheng Jiang,
来源：第六届岭南有机化学论坛 年份：2016
...
[会议论文] 作者：Sheng Jiang,Yiwu Yao,Zhengchao Tu,
来源：2015年全国药物化学学术会议暨第五届中英药物化学学术会议 年份：2015
Histone deacetylases(HDACs)are a family of enzymes that catalyze the deacetylation of lysine side chains in chromatin,and thereby these enzymes are involved in a wide range of biological processes suc...
[会议论文] 作者：Yiwu Yao,Zhengchao Tu,Sheng Jiang,
来源：2015年全国药物化学学术会议暨第五届中英药物化学学术会议 年份：2015
Histone deacetylases(HDACs)are a family of enzymes that remove the acetyl groups of acetylated histones or other nonhistone substrates leading to transcriptional repression,and play important roles in...
Synthesis and Evaluation of Novel Erlotinib-NSAID Conjugates as More Comprehensive Anti-Cancer Agent
[会议论文] 作者：Yanmei Zhang,Micky D.Tortorella,Jinxi Liao,Xiaochu Qin,Tingting Chen,Jinfeng Luo,Jiantong Guan,Zhengchao Tu,
来源：第五届岭南有机化学论坛暨华南理工大学-兰州大学有机化学双边论坛 年份：2015
...
Synthesis and Evaluation of Novel Erlotinib-NSAID Conjugates as More Comprehensive Anti-Cancer Agent
[会议论文] 作者：Yanmei Zhang,Micky D.Tortorella,Jinxi Liao,Xiaochu Qin,Tingting Chen,Jinfeng Luo,Jiantong Guan,Zhengchao Tu,
来源：第五届岭南有机化学论坛暨华南理工大学-兰州大学有机化学双边论坛 年份：2015
In cancer treatment,using a single drug directed towards just one target/mechanism is usually inadequate and overtime disease management usually requires drug combinations targeting multiple cancer pa...
[期刊论文] 作者：Liang Jiang,Yuting Wang,Qian Li,Zhengchao Tu,Sihua Zhu,Sanfang Tu,Zhang Zhang,Ke Ding,Xiaoyun Lu,
来源：药学学报:英文版 年份：2021
Bcr-Abl threonine 315 to isoleucine 315(T315 I)gatekeeper mutation induced drug resistance remains an unmet clinical challenge for the treatment of chronic myeloid leukemia(CML).Chemical degradation of Bcr-AblT315 Iprotein has become a pote......
Discovery of pteridin-7(8H)-one-based Irreversible Inhibitors targeting Epidermal Growth Factor Rece
[会议论文] 作者：Wei Zhou,Xiaofeng Liu,Zhengchao Tu,Lianwen Zhang,Fang Bai,Zhenjiang Zhao,Yufang Xu,Ke Ding,Honglin Li,
来源：第八届全国化学生物学学术会议 年份：2013
The EGFR T790M variant is an important mutation resulting in approximately 50％ of the clinically acquired resistance to approved EGFR inhibitors, such as gefitin...
Design,Synthesis and Biological Evaluation of Novel Inhibitors Targeting EGFRT790M Mutant for Overco
[会议论文] 作者：Shaohua Chang,Ke Ding,Shilin Xu,Tianfeng Xu,Lianwen Zhang,Jinfeng Luo,Xiaoyun Lu,Zhang Zhang,Zhengchao Tu,
来源：中国化学会第十届全国有机合成化学学术研讨会 年份：2012
...
Design,Synthesis and Biological Evaluation of Novel Inhibitors Targeting EGFRT790M Mutant for Overco
[会议论文] 作者：Shaohua Chang,Ke Ding,Shilin Xu,Tianfeng Xu,Lianwen Zhang,Jinfeng Luo,Xiaoyun Lu,Zhang Zhang,Zhengchao Tu,
来源：中国化学会第十届全国有机合成化学学术研讨会 年份：2012
...
Highly potent dipeptidyl peptidase Ⅳ inhibitors derived from Alogliptin through pharmacophore hybrid
[会议论文] 作者：Xie,Xiquan Zhang,Shanchun Wang,Wenhui Hu,Lili Zeng,Shaogao Zeng,Xin Lu,Xin Zhao,Guicheng Zhang,Zhengchao Tu,
来源：2014年广东省药师周大会 年份：2014
The superposition of the DPP-Ⅳ complex revealed that the butynyl group of Linagliptin can be freely switched with the cyanobenzyl group of Alogliptin.Thus, a pharmacophore hybridization of A logliptin...
相关搜索：
